International Journal of Hypertension

International Journal of Hypertension / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 6613231 | https://doi.org/10.1155/2021/6613231

Lin Wang, Mulalibieke Heizhati, Xintian Cai, Mei Li, Zhikang Yang, Zhongrong Wang, Reyila Abudereyimu, Nanfang Li, "Barriers to Access to Treatment for Hypertensive Patients in Primary Health Care of Less Developed Northwest China: A Predictive Nomogram", International Journal of Hypertension, vol. 2021, Article ID 6613231, 11 pages, 2021. https://doi.org/10.1155/2021/6613231

Barriers to Access to Treatment for Hypertensive Patients in Primary Health Care of Less Developed Northwest China: A Predictive Nomogram

Academic Editor: Lanfranco D Elia
Received07 Dec 2020
Accepted03 Apr 2021
Published15 Apr 2021

Abstract

Background. This study aims to evaluate the risk factors associated with untreated hypertension and develop and internally validate untreated risk nomograms in patients with hypertension among primary health care of less developed Northwest China. Methods. A total of 895 eligible patients with hypertension in primary health care of less developed Northwest China were divided into a training set (n = 626) and a validation set (n = 269). Untreated hypertension was defined as not taking antihypertensive medication during the past two weeks. Using least absolute shrinkage and selection operator (LASSO) regression model, we identified the optimized risk factors of nontreatment, followed by establishment of a prediction nomogram. The discriminative ability, calibration, and clinical usefulness were determined using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision analysis. The results were assessed by internal validation in the validation set. Results. Five independent risk factors were derived from LASSO regression model and entered into the nomogram: age, herdsman, family income per member, altitude of habitation, and comorbidity. The nomogram displayed a robust discrimination with an AUC of 0.859 (95% confidence interval: 0.812–0.906) and good calibration. The nomogram was clinically useful when the intervention was decided at the untreated possibility threshold of 7% to 91% in the decision curve analysis. Results were confirmed by internal validation. Conclusions. Our nomogram showed favorable predictive accuracy for untreated hypertension in primary health care of less developed Northwest China and might help primary health care assess the risk of nontreatment in patients with hypertension.

1. Introduction

Hypertension is the leading risk factor for cardiovascular disease (CVD), which remains an important public health problem as one of the top causes of death in China, causing heavy social, familial, and economic dysfunctions [1, 2]. The prevalence of hypertension is about 27.9% in the population aged ≥18 years [3] and up to 41.9% in the population aged ≥35 years in China [4], but the hypertension treatment rate is only 40.7%, which is even unacceptably low (22.1%) in underdeveloped northwest China compared with southeast of China (51.4%) [5, 6].

For hypertensive patients, antihypertension treatment is fundamental to improve health outcomes, minimize their impact, prevent further disability, and reduce health care costs [7, 8]. Despite the fact that hypertension is one of the most common chronic conditions treated in primary care [9] and the fact that the benefit of reducing blood pressure (BP) levels in hypertensive patients has been demonstrated [10, 11], it is untreated in a significant proportion of patients, even those who are aware that they have hypertension. Compared with European and American countries, the treatment rate of hypertension is increasing rather slowly in China owing to the unique social medical system, health care policy, family economic restrictions, traffic obstacle, and so forth [1215]. Therefore, there remain enormous challenges in the understanding and primary prevention of hypertension in China.

Northwest China is economically less developed, with large land area and sparse population density. One-fifth of local residents are leading nomadic or seminomadic lives, making the penetration rate of medical resources low, health awareness poor, and the lifestyle unhealthy [16, 17]. All these factors may lead to higher prevalence of hypertension and its poor treatment especially among residents in stock-raising regions. However, antihypertensive medication nontreatment is affected by multiple determinants such as patient-related factors (e.g., age, sex, education level, and access to health care), socioeconomic factors (e.g., occupation, marital status, emotional support, and family income), and condition-related factors (e.g., health status and comorbidity) [18].

Considering so many associated risk factors, accurate prediction nontreatment tools and early intervention may be the most effective actions toward unsatisfactory treatment. Therefore, this study aimed to identify the risk factors associated with untreated hypertension in the management of hypertension in primary health care of Northwest China and to develop a predictive nomogram to estimate the probability of nontreatment in a given visit, according to five dimensions related to the demographic factors, socioeconomic status, living environment, health-related behaviors, and anthropometric value.

2. Materials and Methods

2.1. Study Design and Population

The cross-sectional study is reported according to the STROBE checklist standards. This study design and methods have been described previously [19]. Briefly, we used four-stage (city/county-district/township-community/village-resident) stratified random sampling method to obtain the study samples aged ≥15 years across Xinjiang, Northwest China, between Augusts 2014 and September 2015. Totally there are 84 sites (60 villages and 24 communities) in 5 rural counties and 2 urban districts including 7276 participants (with response rate >95%) in the survey. The inclusion criteria were as follows:(1)Residents who are willing to participate in the investigation and sign an informed consent form(2)Local inhabitants aged ≥15 years(3)Residing at the current address for ≥6 months(4)Women who are not pregnant

For the current analysis, we excluded participants without response (n = 124) and participants aged <18 years (n = 469). We selected 1,612 hypertensive patients and further excluded patients who were unaware that they have hypertension (n = 717), since patients who were unaware of having hypertension would not be on antihypertensive treatment at the time of survey. Therefore, 895 subjects who were confirmed to be diagnosed with hypertension before the survey of this study were included in the final analysis as shown in Figure 1. The Ethics Committee of People’s Hospital of Xinjiang Uygur Autonomous Region and the Fuwai Hospital Ethics Review Board approved the current study.

2.2. Data Collection and Measurement

Trained study staff used a standardized questionnaire to collect data on demographic characteristics (such as sex, age, and ethnicity), socioeconomic status (occupation, education attainment status, marital status, and family income per member), health-related behaviors (alcohol consumption and cigarette smoking) [19], and hypertensive status (whether it was previously diagnosed by a doctor, whether it has been treated, and whether taking antihypertensive drugs within the previous two weeks).

2.3. Anthropometric Variables

Trained observers measured the body height, weight, waist circumference (WC), and blood pressure (BP) of each participant according to the standardized equipment and procedures. In order to protect the privacy of participants during the anthropometric measurements, we arranged the measurement site in a room with a suitable temperature, and only one participant can enter at a time. In addition, participants wore light clothing, while their weight and waist circumference were measured. Each participant’s BP records were measured by using the automatic sphygmomanometer OMRON HBP-1300 Professional Portable Blood Pressure Monitor (OMRON, Kyoto, Japan) three times on the right upper arm after the participant rested 5 min in a seated position, with 30 seconds between each measurement with an observer present. The mean value of the three measurements was used for analysis. Body mass index (BMI) was calculated as weight divided by the square of height (kg/m2).

2.4. Plasma Glucose and Lipid Measurements

All subjects fasted for ≥8 h, and a 5 mL fasting blood sample was collected. Next, fasting plasma glucose (FPG), triglyceride (TG), total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were tested using standard methods.

2.5. Definitions

Hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or use of antihypertensive medicine within 2 weeks and/or self-reported presence of hypertension [20]. Untreated hypertension was defined as not taking antihypertensive medication during the past two weeks. Occupational status was defined as herdsman and nonherdsman. Education attainment status was categorized into three levels: primary and lower, junior high, and senior high and higher. Marital status was coded as single, married, or separated. Family income per member was categorized into four levels: <¥500/month, ¥500–1000/month, ¥1001–3000/month, and >¥3000/month. Current smokers were defined as participants who have smoked at least 20 packets of cigarettes in their lifetime and are currently smoking cigarettes or smokeless tobacco [19]. Current drinkers were defined as participants who consumed at least once alcoholic beverage per week in the past month. The BMI was further classified into normal, overweight, and obesity if BMI is below 24.0 kg/m2, between 24.0 and 27.9 kg/m2, and ≥28.0 Kg/m2, respectively. Abdominal obesity was defined as WC ≥ 90 cm in men and WC ≥ 85 cm in women. Diabetes was defined as FPG ≥ 7.0 mmol/L or self-reported presence of diabetes. Dyslipidemia was defined as a combination of one or more statuses: TC ≥ 6.22 mmol/L, LDL-C ≥  4.14 mmol/L, HDL-C < 1.04 mmol/L, TG ≥ 2.26 mmol/L, and self-reported presence of dyslipidemia in terms of criteria recommended by Chinese guidelines for the prevention and treatment of dyslipidemia in adults [21]. Comorbidity was defined as a combination of one or more diseases: CVD (coronary heart disease, stroke), diabetes, and dyslipidemia.

2.6. Statistical Analysis

Descriptive data were conducted for 895 subjects at baseline using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL). Continuous variables were presented as means ± standard deviations (M ± SD) and categorical variables were expressed as frequency (n) and proportion (%), and the results were compared using Student’s t-test, the chi-square test, and Mann-Whitney U test to detect the statistical significance, respectively.

Steps of the formulation and assessment of the nomogram were carried out using the package of “rms” in R version 3.5.1 (http://www.r-project.org/) as follows: First, we extracted the training set derived from the 70% (n = 626) of randomized samples of the total sample population for use in building the nomogram. We reserved the remaining 30% (n = 269) as validation set for the validation. The least absolute shrinkage and selection operator (LASSO) method was used to identify independent predictive features from the training set by nonzero coefficients in the LASSO regression model [2224]. Second, we used multivariable logistic regression analysis to build a predicted nomogram based on the selected features from the LASSO regression model [25, 26], with results presented as and odds ratio (OR) with associated 95% confidence interval (95% CI). Third, the discrimination and calibration of the nomogram were assessed by the area under the receiver operating characteristic curve (AUC) and calibration curves plot, respectively [27]. In addition, the nomogram accuracies were evaluated by internal validation, in which we calculated an AUC in the validation set. Finally, to quantify the net benefits at different threshold probabilities in the study, decision curve analysis was conducted in the validation set to determine the usefulness of the nontreatment nomogram [28]. All statistical tests were two-sided, and values < 0.05 were considered to be statistically significant.

3. Results

3.1. Patient Characteristics

In total, 895 patients with mean age of 52.65 ± 17.49 years were enrolled, with women accounting for 52.7%. The baseline characteristics between training and validation sets are displayed in Table 1. No statistically significant differences in age, sex, education level, ethnicity, number of family members, marital status, altitude of habitation, current smokers, current drinkers, BMI, abdominal obesity, and comorbidity were observed between the two sets.


VariablesTraining set (n = 626)Validation set (n = 269)Total (n = 895)P value

Age (years)52.63 ± 17.6152.69 ± 17.2652.65 ± 17.490.963
 <45 y191 (30.5)77 (28.6)268 (29.9)0.820
 45–60 y201 (32.1)91 (33.8)292 (32.6)
 >60 y234 (37.4)101 (37.5)335 (37.5)

Gender, women (n,%)337 (53.8)135 (50.2)472 (52.7)0.316#
Herdsman (n, %)260 (41.5)116 (43.1)376 (42.0)0.659#

Education levels (n, %)
 Primary and lower361 (57.7)159 (59.1)520 (58.1)0.923
 Junior high145 (23.2)60 ( 22.3)205 (22.9)
 Senior high and higher120 (19.2)50 (18.6)170(19.0)

Ethnicity (n, %)
 Han269 (43.0)111 (41.3)380 (42.5)0.198#
 Kazakh90 (14.4)54 (20.1)144 (16.1)
 Tajik74 (11.8)28 (10.4)102 (11.4)
 Others193 (30.8)76 (28.3)269 (30.1)

Number of family members (n, %)
 133 (5.3)10 (3.7)43 (4.8)0.551
 2–4403 (64.4)172 (63.9)575 (64.3)
 ≥5190 (30.4)87 (32.3)277 (30.9)

Marital status (n, %)
 Single64 ( 10.2)21 (7.8)85 (9.5)0.508#
 Married511 (81.6)224 (83.3)735 (82.1)
 Separated51 (8.1)24 (8.9)75 (8.4)

Family income per member
 <¥500/month142 (22.7)65 (24.2)207 (23.1)0.004
 ¥500–1000/month73 (11.7)30 (11.2)103 (11.5)
 ¥1001–3000/month286 (45.7)146 (54.3)432 (48.3)
 >¥3000/month125 (20.0)28 (10.4)153 (17.1)

Altitude of habitation (m)
 <1000387 (61.8)164 (61.0)551 (61.6)0.717
 1000–3000163 (26.0)76 (28.3)239 (26.7)
 >300076 (12.1)29 (10.8)105 (11.7)

Current smokers (n, %)150 (24.0)50 (18.6)200 (22.3)0.077#
Current drinkers (n, %)138 (22.0)46 (17.1)184 (20.6)0.093#

Body mass index27.29 ± 4.3027.25 ± 4.4827.28 ± 4.350.917
 BMI: <23.9 kg/m2124 (19.8)53 (19.7)177 (19.8)0.669
 BMI: 24.0–27.9 kg/m2242 (38.7)112 (41.6)354 (39.6)
 BMI: ≥28.0 kg/m2260 (41.5)104 (38.7)364 (40.7)

Abdominal obesity (n, %)424 (67.7)183 (68.0)607 (67.8%)0.930#
CVD (n, %)21 (3.4)2 (0.7)23 (2.6)0.195#
Diabetes (n, %)91 (14.5)31 (11.5)122 (13.6)0.228#
Dyslipidemia (n, %)113 (18.1)41 (15.2)154 (17.2)0.307#
Comorbidity (n, %)193 (30.8)66 (24.5)259 (28.9)0.057#

Blood pressure (mmHg)
 Systolic blood pressure149.37 ± 20.58152.09 ± 21.34150.19 ± 20.830.073
 Diastolic blood pressure85.67 ± 12.3185.97 ± 13.6885.76 ± 12.730.749

CVD, cardiovascular disease. Student’s t-test for continuous variables. Mann-Whitney U test for ordered multicategorical variables. #Chi-square test for binary variables.

Table S1 showed that the untreated rate among patients with hypertension was 20.9% (187/895). As compared with patients under antihypertensive treatment, those who were untreated were more likely to be older, be herdsmen, experience lower education status, and have less family income per member and less likely to have comorbidity.

3.2. Selected Factors for Model

The samples of the training set were used for building models. Of demographic features, socioeconomic status, living region, health-related behaviors, and anthropometric values, 17 factors were reduced to five potential predictors in the study (∼3 : 1 ratio; Figures 2(a) and 2(b)) and were with nonzero coefficients in the LASSO regression model. These factors included age, herdsman, family income per member, altitude of habitation, and comorbidity (Table 2).


StratificationOR (95% CI) value

Age0.5171.68 (1.27–2.21)<0.001
Herdsman1.0542.87 (1.77–4.64)<0.001
Family income per member−1.6440.19 (0.15–0.25)<0.001
Altitude of habitation1.1343.11 (2.17–4.44)<0.001
Comorbidity−0.7760.46 (0.27–0.78)0.004
Constant−1.9200.147<0.001

OR: odds ratio; CI: confidence interval.
3.3. Development of Predictive Nomogram

The results of multivariable logistic regression analysis were shown in Table 2, which included the above independent predictors. Then, the model was built and presented as the nomogram (Figure 3). We observed that family income per member <¥500/month was corresponding to the highest risk score of 100 points, and second was the altitude of habitation >3000 m (53 points), followed by herdsman (26 points), no comorbidity (19 points), and age > 60 years (18 points).

3.4. Discriminative Ability, Validation, and Calibration of the Nomogram

The AUC for the prediction nomogram was 0.859 (95% CI: 0.812–0.906) (Figure 4), and it was confirmed to be 0.864 (95% CI: 0.794–0.934) through internal validation, indicating the model’s good discrimination. Calibration of the untreated risk nomogram for the prediction of untreated risk in hypertensive patients was performed by the calibration curve plot. When value > 0.05, the calibration ability of the model is good. The calibration curve of the training set was , and the calibration curve of the validation set was , all of which were greater than 0.05, demonstrating that the model had good calibration ability (Figures 5(a) and 5(b)).

3.5. Clinical Use

The decision curve analysis for the untreated nomogram showed that if the threshold probability of a hypertensive patient ranges from 7% to 91%, using this untreated nomogram to predict untreated risk adds more benefit than the scheme (Figure 6).

4. Discussion

Herein, this is the first study in relatively representative patients with hypertension among primary health care of less developed northwest China to develop a predictive nomogram to evaluate the factors influencing the access to treatment for hypertension. Untreated rate of hypertension is still very high among patients with hypertension, despite the existence of universal access and the availability of effective treatments. The nomogram developed is simple (consisting of only five factors; during selection of variables for each block, many were eliminated because they were not associated with nontreatment or because they were strongly collinear with other variables) and shows good standardization and ability to discriminate. Its high sensitivity (85%) is worth mentioning, indicating that the factors included are able, as a whole, to predict properly hypertensive patients who have no access to treatment.

Herdsmen are those who are leading a nomadic or seminomadic lifestyle. Common antihypertension agents are not readily available in many stock-raising regions due to their nomadic lifestyles. In addition, the proportions of individuals who could not afford these drugs are much higher among them, based on their household income [29, 30]. It has also been indicated that hypertensive individuals often stop taking antihypertensive drugs when BP control is achieved [31]. Similar to previous studies, our findings suggested that family income per member <¥500/month was also associated with higher nontreatment. Furthermore, the use of antihypertensive drug treatment patterns by village physicians is different compared with tertiary hospital physicians [31]. Village doctors in stock-raising regions may lack knowledge or willingness to follow new guidelines and might have been entrenched in traditional prescription habits due to obstacles in information exchange [4]. Patients often give up on continuing antihypertensive treatment for suboptimal pharmacotherapy [32]. Therefore, it may explain, at least in part, why untreated rates of hypertension are high.

With the increase in geographical altitude, the population will become sparse, the style of living and production will become more singular, and health needs and access to health care become considerable challenges in high-altitude regions [33, 34]. The presence of hypertension is common in residents living in high-altitude regions [35, 36] and requires pharmacological therapy in the majority of cases in order to manage them properly. Some studies show that the prevalence of polypharmacy and primary health care is associated with the prevalence of chronic diseases [37, 38]. To our surprise, the factor of altitude of habitation is a key point to affect treatment. High altitude may result in poor treatment due to the absence of an adequate health network in high-altitude areas able to properly provide care and necessary BP-lowering agents to the residents [39], limiting the consequences in their antihypertensive performance. It has been reported that about 83 million people reside in highlanders (defined as >2,500 meters above sea level) [40], distributed mainly in South America, Eastern Africa, and Central Asia [41]. The prevalence of hypertension at high-altitude locations is as high as 55.9% [42]. Therefore, given the large number of population from highlanders, the huge burden of hypertension there and its well-established role in cardiovascular risk, further increasing the density of primary care providers or services and the access to medicines for hypertension in high-altitude areas, especially in regions above 3000 m, may enhance treatment in hypertensive patients.

The elderly and hypertensive patients without comorbidities were associated with nontreatment. This may be explained by the fact that elderly people in rural and stock-raising regions have traffic obstacles when they go to town to buy antihypertensive drugs and most elderly farmers or herdsmen generally lose a large part of their economic resources compared with their younger counterparts, which may have led them to take antihypertensive drugs intermittently [31]. Hypertensive patients without comorbidity may be paying less attention to their health condition compared with those with comorbidity, which may also contribute to these patients without comorbidity being a predictor for untreated hypertension. Accordingly, increasing access to health care and strengthening health education and regular follow-up target adherence may be vital ways to further improve hypertension treatment [43, 44].

Our study has several strengths. First, the nontreatment risk prediction tools may provide important insight to clinicians in delivering optimal health care services. Using accessible metrics such as age, occupation, number of family members, altitude of habitation, and information about comorbidity, this tool can help the clinicians, especially primary health providers, to better identify patients who are at high risk of not taking medications as prescribed. Finding such patients is an important step before intervening to improve their adherence. Second, our model showed good accuracy and excellent agreement in training set and validation set, which suggests that it has good transportability and generalizability.

Some limitations in the current report should be kept in mind when interpreting the results. First, the study sample may not stand for all Chinese with hypertension. Patients who are not aware of their hypertensive status were also excluded from the analysis. Second, risk factor analysis may have missed some potential variables that could affect the commence of antihypertensive treatment such as the therapy-related factors (e.g., type of medicine, side effects, and medicine-related questions) and social support. Third, although the robustness of our nomogram was examined with internal validation, we failed to perform external validation, and therefore the generalizability of current data may be limited in other populations and regions/countries and relevant external validation is needed.

5. Conclusions

There is a considerable nontreatment rate among hypertensive patients in primary health care of less developed Northwest China. This study developed a novel nomogram with a relatively good accuracy to help primary health care access the risk of nontreatment in hypertensive patients when they manage these patients. Herdsmen living in high-altitude areas with low family income may be the key population for enhancing antihypertensive treatment.

Data Availability

Materials included in the manuscript, excluding the relevant raw data, will be made freely available to any researchers who wish to use them for noncommercial purposes, while preserving any necessary confidentiality and anonymity.

Ethical Approval

Ethics approval was obtained from Ethics Review Committee of People’s Hospital of Xinjiang Uygur Autonomous Region.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Nanfang Li and Lin Wang contributed to the study design. Nanfang Li, Lin Wang, Mulalibieke Heizhati, Mei Li, Zhikang Yang, Zhongrong Wang, and Reyila Abudereyimu participated in the data collection. Lin Wang and Xintian Cai performed the statistical analysis. Lin Wang drafted the manuscript. Mulalibieke Heizhati critically revised the manuscript. Nanfang Li, Mei Li, Zhikang Yang, Zhongrong Wang, and Reyila Abudereyimu gave important suggestions and did significant changes. All authors reviewed and approved the final version of the paper.

Acknowledgments

This work was supported by a grant from National Key Research and Development Plan Projects (2018YFC1311503). The authors thank all individuals who participated in the present study and also thank all participants of the survey including the population. They acknowledge the Department of Science and Technology of Xinjiang Uygur Autonomous Region of China for funding the project.

Supplementary Materials

Table S1: Baseline characteristics of the treatment and nontreatment groups of the study population. (Supplementary Materials)

References

  1. M. Zhou, H. Wang, X. Zeng et al., “Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017,” The Lancet, vol. 394, no. 10204, pp. 1145–1158, 2019. View at: Publisher Site | Google Scholar
  2. GBD Causes of Death Collaborators, “Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the global burden of disease study,” Lancet, vol. 390, no. 10100, pp. 1151–1210, 2016. View at: Publisher Site | Google Scholar
  3. Z. Wang, Z. Chen, L. Zhang et al., “Status of hypertension in China,” Circulation, vol. 137, no. 22, pp. 2344–2356, 2018. View at: Publisher Site | Google Scholar
  4. W. Li, H. Gu, K. K. Teo et al., “Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China,” Journal of Hypertension, vol. 34, no. 1, pp. 39–46, 2016. View at: Publisher Site | Google Scholar
  5. H. Li, X. Yan, X. Deng et al., “A cross-sectional study of the prevalence, awareness, treatment and control of hypertension in Shenzhen, China,” BMJ Open, vol. 7, no. 6, p. e015206, 2017. View at: Publisher Site | Google Scholar
  6. M. Xu, X. F. Li, D. Goan et al., “Prevalence and predictors of hypertension in the labor force population in China: results from a cross-sectional survey in Xinjiang Uygur autonomous region,” Biomedical and Environmental Sciences : BES, vol. 29, no. 4, pp. 290–294, 2016. View at: Publisher Site | Google Scholar
  7. K. R. Lorig, P. Ritter, A. L. Stewart et al., “Chronic disease self-management program,” Medical Care, vol. 39, no. 11, pp. 1217–1223, 2001. View at: Publisher Site | Google Scholar
  8. T. Bodenheimer, K. Lorig, H. Holman, and K. Grumbach, “Patient self-management of chronic disease in primary care,” JAMA, vol. 288, no. 19, pp. 2469–2475, 2002. View at: Publisher Site | Google Scholar
  9. T. Krause, K. Lovibond, M. Caulfield, T. McCormack, B. Williams, and Guideline Development Group, “Management of hypertension: summary of NICE guidance,” BMJ, vol. 343, p. d4891, 2011. View at: Publisher Site | Google Scholar
  10. H. Arima, “Blood pressure-lowering treatment for primary and secondary prevention of different types of stroke,” Expert Review of Cardiovascular Therapy, vol. 7, no. 6, pp. 627–636, 2009. View at: Publisher Site | Google Scholar
  11. B. M. Psaty, T. Lumley, C. D. Furberg et al., “Health outcomes associated with various antihypertensive therapies used as first-line agents,” JAMA, vol. 289, no. 19, pp. 2534–2544, 2003. View at: Publisher Site | Google Scholar
  12. X. Li, J. Lu, S. Hu et al., “The primary health-care system in China,” The Lancet, vol. 390, no. 10112, pp. 2584–2594, 2017. View at: Publisher Site | Google Scholar
  13. H. Li, K. Liu, J. Gu, Y. Zhang, Y. Qiao, and X. Sun, “The development and impact of primary health care in China from 1949 to 2015: a focused review,” The International Journal of Health Planning and Management, vol. 32, no. 3, pp. 339–350, 2017. View at: Publisher Site | Google Scholar
  14. T. Zhang, Y. Xu, J. Ren, L. Sun, and C. Liu, “Inequality in the distribution of health resources and health services in China: hospitals versus primary care institutions,” International Journal for Equity in Health, vol. 16, no. 1, p. 42, 2017. View at: Publisher Site | Google Scholar
  15. S. Lu, Y. Zhang, Y. Niu, and L. Zhang, “Exploring medical expenditure clustering and the determinants of high-cost populations from the family perspective: a population-based retrospective study from rural China,” International Journal of Environmental Research and Public Health, vol. 15, no. 12, p. 2673, 2018. View at: Publisher Site | Google Scholar
  16. Z. Wang, S. Huang, Y. Zhao, W. Zhao, and X. Liang, “The role of dietary factors in chronic disease control in China,” Zhonghua Yu Fang Yi Xue Za Zhi, vol. 49, no. 8, pp. 757–760, 2015. View at: Google Scholar
  17. L. Wang, N. Li, M. Heizhati et al., “Prevalence, awareness, treatment, and control and related factors of hypertension in multiethnic agriculture, stock-raising, and urban Xinjiang, northwest China: a cross-sectional screening for 47000 adults,” International Journal of Hypertension, vol. 2019, Article ID 3576853, pp. 1–8, 2019. View at: Publisher Site | Google Scholar
  18. S. J. Rolnick, P. A. Pawloski, B. D. Hedblom, S. E. Asche, and R. J. Bruzek, “Patient characteristics associated with medication adherence,” Clinical Medicine & Research, vol. 11, no. 2, pp. 54–65, 2013. View at: Publisher Site | Google Scholar
  19. L. Wang, M. Heizhati, D. Zhang et al., “Excess weight loss is a vital strategy for controlling hypertension among multi-ethnic population in northwest China: a cross-sectional analysis,” Medicine, vol. 98, no. 36, p. e16894, 2019. View at: Publisher Site | Google Scholar
  20. L. S. Liu and Writing Group of the 2018 Chinese Guidelines for the Management of Hypertension, “2018 Chinese guidelines for prevention and treatment of hypertension., “A report of the revision committee of Chinese guidelines for prevention and treatment of hypertension,” Journal of Geriatric Cardiology, vol. 16, pp. 182–245, 2019. View at: Google Scholar
  21. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults, “Chinese guidelines on prevention and treatment of dyslipidemia in adults,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 35, no. 5, pp. 390–419, 2007. View at: Google Scholar
  22. W. Sauerbrei, P. Royston, and H. Binder, “Selection of important variables and determination of functional form for continuous predictors in multivariable model building,” Statistics in Medicine, vol. 26, no. 30, pp. 5512–5528, 2007. View at: Publisher Site | Google Scholar
  23. Z. Li and M. J. Sillanpää, “Overview of LASSO-related penalized regression methods for quantitative trait mapping and genomic selection,” Theoretical and Applied Genetics, vol. 125, no. 3, pp. 419–435, 2012. View at: Publisher Site | Google Scholar
  24. R. Alhamzawi and H. T. M. Ali, “The Bayesian adaptive lasso regression,” Mathematical Biosciences, vol. 303, pp. 75–82, 2018. View at: Publisher Site | Google Scholar
  25. V. P. Balachandran, M. Gonen, J. J. Smith, and R. P. DeMatteo, “Nomograms in oncology: more than meets the eye,” The Lancet Oncology, vol. 16, no. 4, pp. e173–e180, 2015. View at: Publisher Site | Google Scholar
  26. A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas, “How to build and interpret a nomogram for cancer prognosis,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1364–1370, 2008. View at: Publisher Site | Google Scholar
  27. A. Poncet, T. V. Perneger, P. Merlani, M. Capuzzo, and C. Combescure, “Determinants of the calibration of SAPS II and SAPS 3 mortality scores in intensive care: a European multicenter study,” Critical Care (London, England), vol. 21, no. 1, p. 85, 2017. View at: Publisher Site | Google Scholar
  28. V. B. An Calster, L. Wynants, J. Verbeek et al., “Reporting and interpreting decision curve analysis: a guide for investigators,” European Urology, vol. 74, no. 6, pp. 796–804, 2018. View at: Google Scholar
  29. W. L. Chou and Z. Wang, “Regional inequality in China’s health care expenditures,” Health Economics, vol. 18, no. S2, pp. S137–S146, 2009. View at: Publisher Site | Google Scholar
  30. R. Khatib, M. McKee, H. Shannon et al., “Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data,” The Lancet, vol. 387, no. 10013, pp. 61–69, 2016. View at: Publisher Site | Google Scholar
  31. Z. Wang, X. Wang, Z. Chen et al., “Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns,” American Journal of Hypertension, vol. 27, no. 2, pp. 252–259, 2014. View at: Publisher Site | Google Scholar
  32. P. Karakurt and M. Kaşikçi, “Factors affecting medication adherence in patients with hypertension,” Journal of Vascular Nursing: Official Publication of the Society for Peripheral Vascular Nursing, vol. 30, no. 4, pp. 118–126, 2012. View at: Publisher Site | Google Scholar
  33. M. Calderón, R. Alvarado-Villacorta, M. Barrios et al., “Health need assessment in an indigenous high-altitude population living on an island in Lake Titicaca, Perú,” International Journal for Equity in Health, vol. 18, no. 1, p. 94, 2019. View at: Publisher Site | Google Scholar
  34. O. Vega-Hinojosa, M. H. Cardiel, and P. Ochoa-Miranda, “Prevalence of musculoskeletal manifestations and related disabilities in a Peruvian urban population living at high altitude. COPCORD study. Stage I,” Reumatología Clínica (English Edition), vol. 14, no. 5, pp. 278–284, 2018. View at: Publisher Site | Google Scholar
  35. N. Aryal, M. Weatherall, Y. K. D. Bhatta, and S. Mann, “Blood pressure and hypertension in adults permanently living at high altitude: a systematic review and meta-analysis,” High Altitude Medicine & Biology, vol. 17, no. 3, pp. 185–193, 2016. View at: Publisher Site | Google Scholar
  36. L. Wang, N. Li, M. Heizhati et al., “Prevalence, awareness, treatment, control, and related factors of hypertension among Tajik nomads living in pamirs at high altitude,” International Journal of Hypertension, vol. 2020, Article ID 5406485, 2020. View at: Publisher Site | Google Scholar
  37. F. Sganga, D. L. Vetrano, S. Volpato et al., “Physical performance measures and polypharmacy among hospitalized older adults: results from the CRIME study,” The Journal of Nutrition, Health & Aging, vol. 18, no. 6, pp. 616–621, 2014. View at: Publisher Site | Google Scholar
  38. D. Gnjidic, S. N. Hilmer, F. M. Blyth et al., “Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes,” Journal of Clinical Epidemiology, vol. 65, no. 9, pp. 989–995, 2012. View at: Publisher Site | Google Scholar
  39. X. Liu, W. Gao, and H. Yan, “Measuring and decomposing the inequality of maternal health services utilization in western rural China,” BMC Health Services Research, vol. 14, p. 102, 2014. View at: Publisher Site | Google Scholar
  40. F. Leon-Velarde and J. T. Reeves, “International consensus group on chronic mountain sickness,” Advances in Experimental Medicine and Biology, vol. 474, pp. 351–353, 1999. View at: Publisher Site | Google Scholar
  41. C. M. Beall, “Adaptation to high altitude: phenotypes and genotypes,” Annual Review of Anthropology, vol. 43, no. 1, pp. 251–272, 2014. View at: Publisher Site | Google Scholar
  42. X. Zhao, S. Li, S. Ba et al., “Prevalence, awareness, treatment, and control of hypertension among herdsmen living at 4,300 m in Tibet,” American Journal of Hypertension, vol. 25, no. 5, pp. 583–589, 2012. View at: Publisher Site | Google Scholar
  43. M. Van Heuckelum, C. Van den Ende, A. Houterman, C. Heemskerk, S. Van Dulmen, and B. Van den Bemt, “The effect of electronic monitoring feedback on medication adherence and clinical outcomes: a systematic review,” PLoS One, vol. 12, no. 10, p. e0185453, 2017. View at: Publisher Site | Google Scholar
  44. R. Nieuwlaat, N. Wilczynski, T. Navarro et al., “Interventions for enhancing medication adherence,” The Cochrane Database of Systematic Reviews, vol. 2014, no. 11, p. CD000011, 2014. View at: Publisher Site | Google Scholar

Copyright © 2021 Lin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views518
Downloads496
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.